Clofazimine latest market price inquiry in 2025

Clofazimine (Clofazimine) is a drug with dual antibacterial and immunomodulatory effects. It was initially widely used clinically for the combined treatment of leprosy, especially in the management of multibacillary leprosy. With the deepening of research, it has gradually been extended to the treatment of other refractory mycobacterial infections, immune-related diseases and some skin diseases, showing good clinical value.

The core indications of clofazimine are to inhibit the proliferation of mycobacteria and reduce inflammatory reactions. Its stable efficacy and relatively long-term oral safety make it still one of the irreplaceable basic drugs in leprosy treatment programs worldwide. At the same time, due to the immunosuppressive and anti-inflammatory properties of the drug, research in some atypical mycobacterial infections and skin inflammatory diseases has gradually increased, showing the potential to further expand indications.

In the domestic market, clofazimine has been launched and entered the medical insurance catalog, greatly reducing the financial burden on patients. The common specifications are 50 mg and 10 tablets, and the market retail price is about 500 yuan. The specific medical insurance reimbursement ratio and final price need to be determined based on local medical insurance policies and the implementation standards of hospital pharmacies. For patients who need to use this drug for a long time, medical insurance coverage is of great significance. Compared with the domestic market, there are cheaper generic drugs on the market overseas. For example, clofazimine capsules with a specification of 100mg and 100 capsules are priced at about 400 yuan, which has obvious cost-effective advantages. Original drugs and generic drugs are basically the same in terms of drug ingredients and clinical efficacy, so many patients and doctors will choose the appropriate version based on their condition, economic conditions, and accessibility.

Overall, whether it is an original drug or a generic drug, clofazimine is still a key drug in the treatment of leprosy and some mycobacterial infections globally. Its market structure reflects the dual characteristics of local supply and international competition, and also provides patients with more choices.

Reference materials:https://www.novartis.com/our-products/pipeline/clofazimine